FDA Approves Bizengri for Rare Bile Duct Cancer

Follow Drugslib on

By Lori Solomon HealthDay Reporter

Medically reviewed by Drugs.com

via HealthDay

MONDAY, May 11, 2026 -- The U.S. Food and Drug Administration has approved Bizengri (zenocutuzumab-zbco) for the treatment of neuregulin 1 (NRG1) fusion-positive cholangiocarcinoma.

This approval occurred under the National Priority Voucher pilot program and also received Breakthrough Therapy and Orphan Drug designations. Bizengri is the first drug approved for adults with advanced, unresectable, or metastatic cholangiocarcinoma harboring an NRG1 gene fusion with disease progression on or after prior systemic therapy.

The approval was based on data from a single-arm trial of 19 patients with NRG1 fusion-positive cholangiocarcinoma, of whom 36.8 percent had an overall response, ranging in duration from 2.8 to 12.9 months. Serious side effects included infusion-related reactions, interstitial lung disease/pneumonitis, and left ventricular dysfunction, as well as common side effects of diarrhea, musculoskeletal pain, fatigue, nausea, infusion-related reactions, dyspnea, rash, constipation, vomiting, abdominal pain, and edema.

"Patients with this ultra-rare type of cancer desperately need new treatment options," FDA Commissioner Marty Makary, M.D., said in a statement. "Through the national priority voucher pilot program, the FDA is accelerating therapies for rare diseases with unmet medical needs, reviewing applications in significantly shortened timelines."

Approval of Bizengri was granted to Partner Therapeutics.

More Information

Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.

Source: HealthDay

Posted : 2026-05-12 09:38

Read more

Disclaimer

Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.

The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.

Popular Keywords